Subscribe

IVD Medical Holding Limited (1931.HK)

HKD0.64 +0.01 (+1.59%)
CN HKSE Healthcare Medical - Distribution
Address Building 6
Shanghai, CN
CEO Xianya Lin
Website ivdholding.com
IPO 2019-07-12
ISIN KYG4977H1065

Explore sections of this company profile

Description

IVD Medical Holding Limited functions as an investment holding company primarily engaged in the distribution of in vitro diagnostic (IVD) products. Its operations span both Mainland China and global markets. The enterprise structures its activities into three key segments: a Distribution Business, Maintenance Services, and a Self-branded Products Business. The company offers a comprehensive range of IVD analysers, reagents, and other consumables. These are utilized across various diagnostic testing fields, including hematology and body fluid analysis, immunoassay, clinical chemistry, molecular diagnostics, microbiology, and point-of-care testing. Additionally, it supplies haemostasis products and provides specialized solution services for clinical laboratories within hospitals. Its maintenance services include repair, installation, and training for end customers. Under its proprietary IVD brand, the company actively researches, develops, manufactures, and markets IVD analyzers and reagents. Its clientele encompasses hospitals, various healthcare institutions, logistics partners, and independent distributors. Established in 1993, IVD Medical Holding Limited maintains its headquarters in Shanghai, People's Republic of China.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD0.64 +0.01 (+1.59%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
902.4K
Beta
-0.52
Float Shares
549.03M
Free Float %
34.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% -11.11% -22.58% -39.50% -88.97% -72.52% -65.88% -51.02% -76.32% -76.55% -76.55%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.64
Quality scores
Altman Z-Score
1.76
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Distribution: +5.6%
    -10.8% Q4'25: -9.4% (vs Q4'23)
  • ✗
    EPS growth Medical - Distribution: +4.9%
    -87.3% Q4'25: -102.6% (vs Q4'23)
  • ✗
    FCF margin FCF growth · Medical - Distribution: +37.6%
    -35.8% Q4'25: -65.1% (vs Q4'23)
  • ✗
    EBIT margin Medical - Distribution: +3.0%
    +6.4% ★ Q4'25: +4.3% (vs Q4'23)
  • ✗
    ROIC Medical - Distribution: +5.7%
    +2.5% Q4'25: +3.7% (vs Q4'23)
  • ✗
    Share dilution Medical - Distribution: +0.0%
    +8.4% Q4'25: +19.5% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×
    9.30× Q4'25: 5.73× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.47) × ERP
WACC = 34% × Ke + 66% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 0.64
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana.
Revenue
2.33B
est: 2.49B (-6.4%)
2.43B
est: 2.69B (-9.8%)
2.73B
est: 3.18B (-14.0%)
2.75B
est: 3.54B (-22.3%)
2.82B
est: 2.54B (+11.0%)
2.54B
2.54B – 2.54B
+0.0% YoY
2.87B
2.87B – 2.87B
+13.1% YoY
3.50B
3.50B – 3.50B
+21.6% YoY
3.62B
3.62B – 3.62B
+3.6% YoY
EBITDA
331.05M
est: 306.27M (+8.1%)
250.05M
est: 330.76M (-24.4%)
286.17M
est: 390.23M (-26.7%)
349.66M
est: 434.91M (-19.6%)
207.28M
est: 297.33M (-30.3%)
297.33M
297.33M – 297.33M
+0.0% YoY
336.16M
336.16M – 336.16M
+13.1% YoY
408.92M
408.92M – 408.92M
+21.6% YoY
423.52M
423.52M – 423.52M
+3.6% YoY
EBIT
281.61M
est: 278.11M (+1.3%)
227.06M
est: 300.35M (-24.4%)
259.05M
est: 354.36M (-26.9%)
314.37M
est: 394.93M (-20.4%)
180.30M
est: 268.56M (-32.9%)
268.56M
268.56M – 268.56M
+0.0% YoY
303.64M
303.64M – 303.64M
+13.1% YoY
369.36M
369.36M – 369.36M
+21.6% YoY
382.55M
382.55M – 382.55M
+3.6% YoY
Net Income
275.00M
est: 564.94M (-51.3%)
158.72M
est: 343.19M (-53.8%)
174.54M
est: 401.98M (-56.6%)
210.00M
est: 451.80M (-53.5%)
34.93M
est: 624.33M (-94.4%)
624.33M
624.33M – 624.33M
+0.0% YoY
397.05M
397.05M – 397.05M
-36.4% YoY
479.51M
479.51M – 479.51M
+20.8% YoY
500.84M
500.84M – 500.84M
+4.4% YoY
SGA
221.59M
est: 252.65M (-12.3%)
249.10M
est: 272.86M (-8.7%)
307.22M
est: 321.92M (-4.6%)
272.85M
est: 358.77M (-23.9%)
380.46M
est: 274.06M (+38.8%)
274.06M
274.06M – 274.06M
+0.0% YoY
309.86M
309.86M – 309.86M
+13.1% YoY
376.92M
376.92M – 376.92M
+21.6% YoY
390.38M
390.38M – 390.38M
+3.6% YoY
EPS
0.24
est: 0.38 (-36.5%)
0.12
est: 0.23 (-47.7%)
0.13
est: 0.27 (-51.6%)
0.16
est: 0.30 (-47.0%)
0.02
est: 0.39 (-94.4%)
0.39
0.39 – 0.39
+0.0% YoY
0.25
0.25 – 0.25
-36.4% YoY
0.30
0.30 – 0.30
+20.8% YoY
0.31
0.31 – 0.31
+4.4% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B+ 3/5 5/5 3/5 4/5 1/5 1/5 4/5
2026-05-28 B+ 3/5 5/5 3/5 4/5 1/5 1/5 4/5
2026-05-27 B+ 3/5 5/5 3/5 4/5 2/5 1/5 4/5
2026-05-26 B+ 3/5 5/5 3/5 4/5 2/5 1/5 4/5
2026-05-22 B+ 3/5 5/5 3/5 4/5 1/5 1/5 4/5
2026-05-21 B+ 3/5 5/5 3/5 4/5 1/5 1/5 4/5
2026-05-20 B+ 3/5 5/5 3/5 4/5 1/5 1/5 4/5
2026-05-19 B+ 3/5 5/5 3/5 4/5 1/5 1/5 4/5
2026-05-18 B+ 3/5 5/5 3/5 4/5 1/5 1/5 4/5
2026-05-15 B+ 3/5 5/5 3/5 4/5 1/5 1/5 4/5
2026-05-14 B+ 3/5 5/5 3/5 4/5 1/5 1/5 4/5
2026-05-13 B 3/5 5/5 3/5 3/5 1/5 1/5 4/5
2026-05-12 B 3/5 5/5 3/5 3/5 1/5 1/5 4/5
2026-05-11 B 3/5 5/5 3/5 3/5 1/5 1/5 4/5
2026-05-08 B 3/5 5/5 2/5 3/5 1/5 1/5 4/5
2026-05-07 B 3/5 5/5 2/5 3/5 1/5 1/5 4/5
2026-05-06 B 3/5 5/5 2/5 3/5 1/5 1/5 4/5
2026-05-05 B 3/5 5/5 2/5 3/5 1/5 1/5 4/5
2026-05-04 B 3/5 5/5 2/5 3/5 1/5 1/5 4/5
2026-04-30 B 3/5 5/5 2/5 4/5 1/5 1/5 4/5
2026-04-29 B 3/5 5/5 2/5 4/5 1/5 1/5 4/5
2026-04-28 B 3/5 5/5 2/5 4/5 1/5 1/5 4/5
2026-04-27 B 3/5 5/5 2/5 4/5 1/5 1/5 4/5
2026-04-24 B 3/5 5/5 2/5 4/5 1/5 1/5 4/5
2026-04-23 B 3/5 5/5 2/5 4/5 1/5 1/5 4/5
2026-04-22 B 3/5 5/5 2/5 4/5 1/5 1/5 4/5
2026-04-21 B 3/5 5/5 2/5 4/5 1/5 1/5 4/5
2026-04-20 B 3/5 5/5 2/5 4/5 1/5 1/5 4/5
2026-04-17 B 3/5 5/5 2/5 4/5 1/5 1/5 4/5
2026-04-16 B 3/5 5/5 2/5 4/5 1/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
242.31M
OE per share TTM
0.17
Owner's Yield
20.82%
Maintenance CapEx ratio
10.35%
Maint CapEx / Avg PPE
3.8%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 1 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Avantis Emerging Markets Equity ETF AVEM 0.00% 249.35 0.33%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
208.9K
Shares Outstanding
1.60B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Xianya Lin GM & Executive Director 3M male
Siu Kei Chan Executive Director & Company Secretary 1M male
Bo Yang Financial Controller — male
Xiao Yi Chief Scientist & Executive Director — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Distribution